<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753957</url>
  </required_header>
  <id_info>
    <org_study_id>20D.1094</org_study_id>
    <nct_id>NCT04753957</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Progesterone in Pregnancy-2</brief_title>
  <acronym>PiP-2</acronym>
  <official_title>Pharmacokinetics of Progesterone in Pregnancy-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the local pharmacokinetics of progesterone in&#xD;
      pregnancy through evaluation of progesterone levels in maternal serum, endometrium, and&#xD;
      cordblood in pregnant patients undergoing scheduled cesarean delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this pilot study is to evaluate the local pharmacokinetics of progesterone&#xD;
      in pregnancy through evaluation of progesterone levels in maternal serum, endometrium, and&#xD;
      cordblood in pregnant patients undergoing scheduled cesarean delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial (ng/mg) progesterone time/concentration profile</measure>
    <time_frame>12 hours</time_frame>
    <description>Concentration of progesterone in endometrium, sampled at time of scheduled c-section</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma (ng/ml) progesterone time/concentration profile</measure>
    <time_frame>12 hours</time_frame>
    <description>concentration of serum progesterone, sampled at time of scheduled c-section</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effect survey</measure>
    <time_frame>24hr after delivery</time_frame>
    <description>survey of side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Vaginal progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg micronized vaginal progesterone placed 7am prior to scheduled cesarean delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention, scheduled cesarean delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micronized Progesterone</intervention_name>
    <description>200mg micronized progesterone placed vaginally</description>
    <arm_group_label>Vaginal progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18yo&#xD;
&#xD;
          -  Singleton gestation, ≥36 0/7 weeks gestation&#xD;
&#xD;
          -  Scheduled cesarean delivery at Thomas Jefferson University Hospital or affiliate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to vaginal progesterone suppository&#xD;
&#xD;
               -  Active hepatic disease&#xD;
&#xD;
               -  Prior or current thrombus&#xD;
&#xD;
               -  Known adverse reaction to progesterone&#xD;
&#xD;
               -  Peanut allergy&#xD;
&#xD;
          -  Bleeding disorder (such as thrombophilia)&#xD;
&#xD;
          -  Use of 17-hydroxyprogesterone caproate in the pregnancy&#xD;
&#xD;
          -  Use of vaginal progesterone in the pregnancy&#xD;
&#xD;
          -  History of adverse reaction to progesterone&#xD;
&#xD;
          -  Current vaginitis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupsa C Boelig, MD</last_name>
      <phone>215-955-9196</phone>
      <email>rupsa.boelig@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD may be requested following trial completion and publication with appropriate data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Following trial completion and publication</ipd_time_frame>
    <ipd_access_criteria>Data sharing agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

